| Autor: |
Conner, Elaine, Miles, Allen M., Aiko, Satoshi, Grisham, Matthew B. |
| Zdroj: |
BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals, and Gene Therapy; June 1995, Vol. 3 Issue: 6 p438-449, 12p |
| Abstrakt: |
There is a large body of circumstantial evidence to suggest that reactive oxygen metabolites are important mediators of the pathophysiology observed in a variety of inflammatory disorders. Intravenous administration of certain anti-oxidants with well-defined mechanisms of action, for example Superoxide dismutase and catalase, has been suggested as a possible mode of therapy for some inflammatory disorders. Unfortunately, the circulating half-lives of these enzymes are very short. This limits the use of these compounds to only very acute inflammatory conditions, or requires multiple injections or continuous infusion over long periods of time in more chronic conditions. The development and use of antioxidants with well-characterised mechanisms of action that can be administered over many days or weeks should prove useful in defining a role for reactive oxygen metabolites in inflammatory tissue injury. These agents may also be valuable as pharmacological agents in treating these disease processes. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink